News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RITA Medical Systems, Inc. (RITA) To Pre-Pay $6.5 Million In Debt Related To Horizon Medical Products (HMP) Merger


10/19/2005 5:12:01 PM

MOUNTAIN VIEW, Calif., Jan. 7 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. today announced that its wholly owned subsidiary Horizon Medical Products, Inc. has entered into an agreement allowing it to repay $6.5 million in debt held by creditors of Horizon. The eight percent notes, which are expected to be paid in full by mid-February 2005, are due in July 2005.

Joseph DeVivo, President and CEO of RITA Medical Systems, commented, "Our decision to pay off the debt early made sense in a number of ways. We believe that paying down debt is a prudent use of cash, resulting in a healthier balance sheet and reduced interest expense. We also expect that combined with our continued operational progress this reduction in debt will help us meet our objective of achieving profitability."

In order to pay off these notes in full, Horizon obtained an agreement from ComVest Venture Partners, L.P., and Medtronic, Inc., Horizon's two majority debt holders, to, among other things, waive their rights to receive a pro rata portion of any payment made against the principal amount of any portion of the outstanding Horizon debt.

About RITA Medical Systems, Inc.

RITA Medical Systems develops manufactures and markets innovative products for cancer patients including radio frequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex(R) technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radio frequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.

The statements in this news release related to the Company's planned prepayment of outstanding debt, its achievement of profitability, the benefits of its merger with Horizon and its future financial and operating performance are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.

Contact: Allen & Caron Inc. RITA Medical Systems, Inc. Jill Bertotti (investors) Don Stewart, Chief Financial Officer jill@allencaron.com Stephen Pedroff, VP Marketing Communications 949-474-4300 650-314-3400 dstewart@ritamed.comspedroff@ritamed.com SurfMedia Communications Juliana Minsky (media) jm@surfmedia.com 805-962-3700

RITA Medical Systems, Inc.

CONTACT: investors, Jill Bertotti of Allen & Caron Inc.,+1-949-474-4300, jill@allencaron.com, or media, Juliana Minsky of SurfMediaCommunications, +1-805-962-3700, jm@surfmedia.com, both for RITA MedicalSystems, Inc.; or Don Stewart, Chief Financial Officer, dstewart@ritamed.com,or Stephen Pedroff, VP Marketing Communications, spedroff@ritamed.com, both ofRITA Medical Systems, Inc., +1-650-314-3400


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES